A patient-specific cognitive behavioral therapy and lifestyle counseling intervention can significantly improve psychological outcomes in type 2 diabetes patients with depression and/or regimen-related distress, say researchers.
Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.
Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.
The strongest predictors for mortality and cardiovascular disease disease in patients with type 1 diabetes are generally modifiable cardiometabolic risk factors, researchers report.
Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.
Findings from the YOMEGA trial indicate that the one anastomosis gastric bypass procedure is noninferior to standard Roux-en-Y gastric bypass in terms of weight loss and metabolic outcomes.
Data from the TrialNet Pathway to Prevention study shows that monitoring high-risk relatives of people with type 1 diabetes markedly reduces the risk for those who develop the condition presenting with diabetic ketoacidosis.
Following the positive 2-year results of DiRECT, this symposium shared the first-hand experiences of a dietician, a general practitioner, and a person with diabetes who participated in the DiRECT study.
Measuring C-peptide in everyone a minimum of 3 years after a clinical diagnosis of type 1 diabetes can result in some people being reclassified with other forms of diabetes, researchers report.
The latest update from the UK’s National Health Service Diabetes Prevention Programme shows that persistence pays, and reveals weight loss and a reduction in glycated hemoglobin levels for people who have so far completed the intervention.
Just over a third of people who undertook a period on a very-low-calorie diet in the DiRECT trial to tackle type 2 diabetes are in remission 24 months later, the investigators have reported.
A behavioral intervention has lasting effects on physical activity levels, fitness, and vascular risk in people with type 2 diabetes, show the 3-year results of the randomized Italian Diabetes and Exercise Study 2.
Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.
Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.
Real-world data show that people with type 2 diabetes struggle to attain their glycated hemoglobin targets, despite these commonly being individualized.
Responsiveness to text message reminders about blood glucose monitoring is associated with glycemic benefit among adolescents with type 1 diabetes, study findings indicate.
Empagliflozin significantly reduces glycated hemoglobin, blood pressure, and bodyweight versus placebo in African–American patients with type 2 diabetes and hypertension, phase III trial data show.
Agreement between five currently recommended definitions of intermediate hyperglycemia, or prediabetes, is poor, and their sensitivity for predicting type 2 diabetes is low, study findings indicate.
Giving children continuous glucose monitoring from the point of diabetes diagnosis gives their caregivers greater confidence to manage hypoglycemia and reduces their diabetes-related distress, shows a randomized trial.